
22 Jul MaxCyte
Sarah Meeks, Senior Vice President, Business Development
Oct. 11 | 5:30pm | Rentschler ATMP Ballroom
Rockville, MD
(NASDAQ: MXCT)
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative, cell-based research. MaxCyte builds best-in-class technology designed to facilitate complex engineering of a wide variety of cells and to drive the rapidly expanding cell therapy market forward. For over 20 years, MaxCyte has been perfecting the art of cell-engineering and venturing beyond today’s process to innovate tomorrow’s solutions. Let’s Build Better Cells Together.